Source-grounded facts extracted from LABCORP HOLDINGS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LABCORP HOLDINGS INC. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.
“Proposal 3. The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”
LABCORP HOLDINGS INC. shareholders approved Advisory (non-binding) vote on the compensation of the Company’s named executive officers.
“Proposal 2. The Company’s shareholders approved in an advisory (non-binding) vote, the compensation of the Company’s named executive officers.”
LABCORP HOLDINGS INC. shareholders approved Election of Directors to the Board of Directors for a term expiring at the 2027 Annual Meeting.
“Proposal 1. The Company’s shareholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for the term expiring at the 2027 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation, or removal:”
LABCORP HOLDINGS INC. reported first quarter ended March 31, 2026 results: revenue $3.54 billion, net income Net Earnings Attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8, EPS $3.35. Guidance raised.
“Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance • Results from Operations for first quarter 2026 versus first quarter 2025: ◦ Revenue: $3.54 billion vs. $3.35 billion, up 5.8% ◦ Diluted EPS: $3.35 vs. $2.52, up 32.8% ◦ Adjusted EPS: $4.25 vs. $3.84, up 10.6% • Raised Full-Year Enterprise Revenue and Adjusted EPS guidance: ◦ Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint ◦ Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint”
LABCORP HOLDINGS INC. entered into Credit Agreement with Wells Fargo Bank, National Association valued at $750,000,000 (effective 2026-03-20).
“Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank, National Association, as syndication agent, and the lenders from time to time party thereto, which provides for a $750,000,000 senior unsecured term loan (the “Term Loan”) scheduled to mature on March 20, 2028.”
LABCORP HOLDINGS INC. incurred term loan of $750,000,000 with Wells Fargo Bank, National Association (as administrative agent), Wells Fargo Securities, LLC (as joint lead arranger and sole bookrunner), PNC Capital Markets LLC (as joint lead arranger), PNC Bank, National Association (as syndication agent), and the lenders from time to time party thereto at floating rate equal to either (i) a SOFR-based rate plus a margin of 0.700% or ( maturing March 20, 2028.
“On March 20, 2026 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank, National Association, as syndication agent, and the lenders from time to time party thereto, which provides for a $750,000,000 senior unsecured term loan (the “Term Loan”) scheduled to mature on March 20, 2028.”
LABCORP HOLDINGS INC. amended Receivables Purchase Agreement with PNC Bank, National Association valued at $125 million accordion facility (effective 2026-01-28).
“On January 28, 2026, Labcorp Holdings Inc. (the “Company”) amended its receivables purchase agreement (as amended, the “Receivables Purchase Agreement”) by entering into the Second Amendment to the Receivables Purchase Agreement (the “RPA Amendment”), among Labcorp Receivables LLC (“Labcorp Receivables”), Laboratory Corporation of America Holdings, PNC Bank, National Association, as administrative agent and the other parties thereto and acknowledged and agreed by the Company.”
LABCORP HOLDINGS INC. amended credit facility of increased from $300 million to $700 million with PNC Bank, National Association, as administrative agent at equal to the CP Rate (as defined in the Receivables Purchase Agreement) plus an.
“e agreement (as amended, the “Receivables Purchase Agreement”) by entering into the First Amendment to the Receivables Purchase Agreement (the “RPA Amendment”), among Labcorp Receivables LLC (“Labcorp Receivables”), Laboratory Corporation of America Holdings, PNC Bank, National Association, as administrative agent and the other parties party thereto and acknowledged and agreed by the Company.”
Glenn Eisenberg retired as Executive Vice President and Chief Financial Officer at LABCORP HOLDINGS INC..
“On November 19, 2024, Labcorp Holdings Inc. (“Labcorp”) announced that on November 15, 2024, Glenn Eisenberg notified Labcorp of his intention to retire from Labcorp effective April 30, 2025.”
Julia Wang was appointed as Executive Vice President and Chief Financial Officer at LABCORP HOLDINGS INC..
“Julia Wang, age 54, was appointed to the position of Executive Vice President and Chief Financial Officer ("CFO").”
LABCORP HOLDINGS INC. underwent a change of control involving Laboratory Corporation of America Holdings (closed 2024-05-17).
“On May 17, 2024, Labcorp implemented the Reorganization pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated as of May 17, 2024, among Labcorp, Labcorp Holdings Inc., a Delaware corporation (“Labcorp Holdings”) and Radiance Merger Sub Inc., a Delaware corporation and direct, wholly owned subsidiary of Labcorp Holdings (“Merger Sub”).”
LABCORP HOLDINGS INC. entered into Guarantor Joinder Agreement with Bank of America, N.A. (effective 2024-05-17).
“On May 17, 2024, Labcorp Holdings entered into the Guarantor Joinder Agreement (the “Guarantor Joinder Agreement"), pursuant to which, among other things, Labcorp Holdings provided a full and unconditional guarantee of Labcorp’s obligations under the Third Amended and Restated Credit Agreement”
LABCORP HOLDINGS INC. entered into Seventeenth Supplemental Indenture with U.S. Bank Trust Company, National Association (effective 2024-05-17).
“on May 17, 2024, Labcorp, Labcorp Holdings and U.S. Bank Trust Company, National Association (the “Trustee”) entered into a seventeenth supplemental indenture (the “Seventeenth Supplemental Indenture") to the indenture, dated as of November 19, 2010 between Labcorp and the Trustee”
LABCORP HOLDINGS INC. entered into Merger Agreement with Merger Sub (effective 2024-05-17).
“On May 17, 2024, Labcorp completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.”
LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal regarding report on transport of nonhuman primates at the 2024-05-14 meeting.
“Proposal 5. The Company's shareholders did not approve the shareholder proposal seeking an annual Board report on the transport of nonhuman primates within the United States. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,787,586 64,071,818 943,785 6,254,885”
LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal regarding policy on golden parachutes at the 2024-05-14 meeting.
“Proposal 4. The Company's shareholders did not approve the shareholder proposal requesting adoption of a policy regarding shareholder opportunity to vote on excessive golden parachutes. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,219,140 65,530,226 53,823 6,254,885”
LABCORP HOLDINGS INC. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2024-05-14 meeting.
“Proposal 3. The Company's shareholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 76,120,507 832,250 105,317 0”
LABCORP HOLDINGS INC. shareholders approved Advisory vote on executive compensation at the 2024-05-14 meeting.
“Proposal 2. The Company's shareholders approved in an advisory (non-binding) vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 65,007,331 5,566,884 228,974 6,254,885”
LABCORP HOLDINGS INC. shareholders approved Election of Directors at the 2024-05-14 meeting.
“Proposal 1. The Company's shareholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for the term expiring at the 2025 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation, or removal: Votes For Votes Against Abstentions Broker Non-Votes Adam H. Schechter 66,696,331 3,866,647 240,211 6,254,885”
LABCORP HOLDINGS INC. reported first quarter ended March 31, 2024 results: revenue $3.18 billion, net income $228.3 million, EPS $2.69. Guidance raised.
“Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance • Results from Continuing Operations for first quarter 2024 versus last year: ◦ Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% ◦ Diluted EPS: $2.69 versus $2.34 ◦ Adjusted EPS: $3.68 versus $3.46 • Full-Year 2024 Guidance: Raised midpoint and”
LABCORP HOLDINGS INC. reported the fourth quarter and year ending Dec. 31, 2023 results: revenue $3.03 billion, net income $(166.8) million, EPS $(1.95).
“Revenue for the quarter was $3.03 billion, an increase of 3.5% from $2.93 billion in the fourth quarter of 2022.”
LABCORP HOLDINGS INC. reported the third quarter ended September 30, 2023 results: revenue $3.06 billion, net income $183.6 million, EPS $2.11. Guidance reaffirmed.
“Guidance • Third quarter revenue grew 6.6% versus last year as the Base Business grew 14.0%. Results from Continuing Operations for third quarter versus last year: ◦ Revenue: $3.06 billion versus $2.87 billion ◦ Diluted EPS: $2.11 versus $3.06 ◦ Adjusted EPS: $3.38 versus $4.01 ◦ Free Cash Flow: $170.6 million versus $170.2 million • Full-Year 2023 Guidance from”
Paul Kirchgraber resigned as Senior Advisor to the CEO at LABCORP HOLDINGS INC..
“As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other opportunities.”
LABCORP HOLDINGS INC. reported Full Year 2023 results: EPS $13.00 to $14.00. Guidance initiated.
“Full-Year 2023 Guidance from Continuing Operations: Adjusted EPS of $13.00 to $14.00 and Free Cash Flow of $0.8 billion to $1.0 billion”
LABCORP HOLDINGS INC. completed a disposition involving Fortrea Holdings Inc. (closed 2023-06-30).
“On June 30, 2023 (the “Distribution Date”) at 11:59 p.m., Burlington, North Carolina time, Laboratory Corporation of America Holdings (the “Company” or “Labcorp”) completed the previously announced separation (the “spinoff”) of Fortrea Holdings Inc. (“Fortrea”) from the Company.”
LABCORP HOLDINGS INC. entered into Transition Services Agreement with Fortrea.
“On July 3, 2023, Fortrea’s common stock will begin trading on the NASDAQ Stock Market under the ticker symbol “FTRE.” Item 1.01 Entry into a Material Definitive Agreement In connection with the spinoff, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company’s relationship with Fortrea after the spinoff, including the following agreements: • a Separation and Distribution Agreement; • a Tax Matters Agreement; • an Employee Matters Agreement; and • a Transition Services Agreement.”
LABCORP HOLDINGS INC. entered into Employee Matters Agreement with Fortrea.
“On July 3, 2023, Fortrea’s common stock will begin trading on the NASDAQ Stock Market under the ticker symbol “FTRE.” Item 1.01 Entry into a Material Definitive Agreement In connection with the spinoff, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company’s relationship with Fortrea after the spinoff, including the following agreements: • a Separation and Distribution Agreement; • a Tax Matters Agreement; • an Employee Matters Agreement; and • a Transition Services Agreement.”
LABCORP HOLDINGS INC. entered into Tax Matters Agreement with Fortrea.
“On July 3, 2023, Fortrea’s common stock will begin trading on the NASDAQ Stock Market under the ticker symbol “FTRE.” Item 1.01 Entry into a Material Definitive Agreement In connection with the spinoff, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company’s relationship with Fortrea after the spinoff, including the following agreements: • a Separation and Distribution Agreement; • a Tax Matters Agreement; • an Employee Matters Agreement; and • a Transition Services Agreement.”
LABCORP HOLDINGS INC. entered into Separation and Distribution Agreement with Fortrea.
“On July 3, 2023, Fortrea’s common stock will begin trading on the NASDAQ Stock Market under the ticker symbol “FTRE.” Item 1.01 Entry into a Material Definitive Agreement In connection with the spinoff, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company’s relationship with Fortrea after the spinoff, including the following agreements: • a Separation and Distribution Agreement; • a Tax Matters Agreement; • an Employee Matters Agreement; and • a Transition Services Agreement.”
Paul B. Rothman was appointed as member of the Board at LABCORP HOLDINGS INC..
“Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023.”
LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal requesting that the Board issue a report on known risks of fulfilling information requests and mitigation strategies at the 2023-05-11 meeting.
“Proposal 7. The Company’s shareholders did not approve the shareholder proposal requesting that the Board issue a report on known risks of fulfilling information requests and mitigation strategies. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,017,249 59,942,620 2,431,234 6,276,937”
LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal seeking an annual Board report on the transport of nonhuman primates within the United States at the 2023-05-11 meeting.
“Proposal 6. The Company’s shareholders did not approve the shareholder proposal seeking an annual Board report on the transport of nonhuman primates within the United States. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,481,149 64,554,771 1,355,183 6,276,937”
LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal regarding separation of Board Chairman and CEO roles at the 2023-05-11 meeting.
“Proposal 5. The Company’s shareholders did not approve the shareholder proposal seeking adoption of a policy regarding the separation of the roles of Board Chairman and Chief Executive Officer. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 22,466,745 50,687,575 236,783 6,276,937”
LABCORP HOLDINGS INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-11 meeting.
“Proposal 4. The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 79,052,094 467,675 148,271 0”
LABCORP HOLDINGS INC. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation (Say-on-Pay Frequency) at the 2023-05-11 meeting.
“Proposal 3. The Company’s shareholders voted, on an advisory (non-binding) basis, on the frequency of future advisory shareholder votes on the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: 1 Year 2 Years 3 Years Abstentions 70,906,564 135,958 2,182,567 166,014”
LABCORP HOLDINGS INC. shareholders approved Advisory vote on the compensation of named executive officers (Say-on-Pay) at the 2023-05-11 meeting.
“Proposal 2. The Company’s shareholders approved in an advisory (non-binding) vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 67,568,231 5,578,194 244,678 6,276,937”
LABCORP HOLDINGS INC. shareholders approved Election of Directors at the 2023-05-11 meeting.
“Proposal 1. The Company’s shareholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for the term expiring at the 2024 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation, or removal: Votes For Votes Against Abstentions Broker Non-Votes Adam H. Schechter 68,729,165 4,372,842 289,096 6,276,937 Kerrii B. Anderson 63,175,243 9,331,550 884,310 6,276,937 Jean-Luc Bélingard 69,825,608 3,418,652 146,843 6,276,937 Jeffrey A. Davis 73,107,712 137,541 145,850 6,276,937 D. Gary Gilliland, M.D., Ph.D. 73,108,618 138,045 144,440 6,276,937 Kirsten M. Kliphouse 73,145,363 99,011 146,729 6,276,937 Garheng Kong, M.D., Ph.D. 64,090,817 9,150,913 149,373 6,276,937 Peter M. Neupert 71,525,965 1,715,064 150,074 6,276,937 Richelle P. Parham 71,663,209 1,581,561 146,333 6,276,937 Kathryn E. Wengel 72,539,971 706,463 144,669 6,276,937 R. Sander”
Brian J. Caveney was appointed as Executive Vice President, President Early Development & Chief Medical and Scientific Officer at LABCORP HOLDINGS INC..
“on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.”
Mark S. Schroeder was appointed as Executive Vice President, President Diagnostics & Chief Operations Officer at LABCORP HOLDINGS INC..
“on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.”
Brian J. Caveney was appointed as Executive Vice President, President Early Development & Chief Medical and Scientific Officer at LABCORP HOLDINGS INC..
“Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.”
Mark S. Schroeder was appointed as Executive Vice President, President Diagnostics & Chief Operations Officer at LABCORP HOLDINGS INC..
“Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.”
LABCORP HOLDINGS INC. updated its full-year 2023 guidance (reaffirmed).
“• Full-Year 2023 Guidance: Adjusted EPS narrowed to $16.25 to $17.75 with midpoint unchanged and Free Cash Flow remains at $1.0 billion to $1.2 billion”
LABCORP HOLDINGS INC. updated its guidance (initiated).
“Full-Year 2023 Guidance: Adjusted EPS of $16.00 to $18.00 and Free Cash Flow of $1.0 billion to $1.2 billion”
LABCORP HOLDINGS INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue $14.88 billion, net income $1.28 billion, EPS $13.97.
“for share repurchases, bringing the total available authorization to approximately $1.53 billion. 2 Consolidated Results Fourth Quarter Results Revenue for the quarter was $3.67 billion, a decrease of (9.4%) from $4.06 billion in the fourth quarter of 2021. The decrease was due to organic revenue of (9.4%) and foreign currency translation of (1.3%), partially”
Paul Kirchgraber departed as EVP and CEO of Drug Development business segment at LABCORP HOLDINGS INC..
“Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.”
Thomas Pike was appointed as President and Chief Executive Officer of Drug Development Clinical Development business unit at LABCORP HOLDINGS INC..
“Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023”
Kirsten M. Kliphouse was appointed as Director at LABCORP HOLDINGS INC..
“Laboratory Corporation of America Holdings (“Labcorp”) today announced that on October 12, 2022, Labcorp’s Board of Directors (the “Board”) appointed Kirsten M. Kliphouse as a member of the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.